TC Biopharm (Holdings) Plc Sponsored ADR ( (TCBP) ) has shared an announcement.
On March 21, 2025, TC BioPharm announced that it received a notice from the Nasdaq Hearings Panel regarding the delisting of its securities due to non-compliance with Nasdaq’s minimum bid price rule. The company’s securities will be suspended from trading on Nasdaq starting March 24, 2025, and are expected to trade on the OTC Markets from the same date. This transition will not affect the company’s reporting obligations with the SEC. The delisting reflects challenges in maintaining market requirements but does not alter the company’s commitment to its research and development initiatives.
More about TC Biopharm (Holdings) Plc Sponsored ADR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company specializing in the development of gamma-delta T-cell therapies for cancer treatment. The company is a leader in this field and is conducting advanced clinical trials, including a pivotal Phase 2b/3 trial for acute myeloid leukemia using its proprietary CryoTC technology.
YTD Price Performance: -84.30%
Average Trading Volume: 277,743
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $40.3K
Learn more about TCBP stock on TipRanks’ Stock Analysis page.